These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7907571)

  • 1. Effectiveness of two methods for informing schizophrenic patients about neuroleptic medication.
    Kleinman I; Schachter D; Jeffries J; Goldhamer P
    Hosp Community Psychiatry; 1993 Dec; 44(12):1189-91. PubMed ID: 7907571
    [No Abstract]   [Full Text] [Related]  

  • 2. Informed consent and tardive dyskinesia. Long-term follow-up.
    Kleinman I; Schachter D; Jeffries J; Goldhamer P
    J Nerv Ment Dis; 1996 Sep; 184(9):517-22. PubMed ID: 8831640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive dyskinesia and informed consent: myths and realities.
    Munetz MR; Roth LH; Cornes CL
    Bull Am Acad Psychiatry Law; 1982; 10(2):77-88. PubMed ID: 6129012
    [No Abstract]   [Full Text] [Related]  

  • 4. Informed consent and tardive dyskinesia.
    Kleinman I; Schachter D; Koritar E
    Am J Psychiatry; 1989 Jul; 146(7):902-4. PubMed ID: 2568093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tardive dyskinesia, impaired recall, and informed consent.
    Ganguli R; Raghu U
    J Clin Psychiatry; 1985 Oct; 46(10):434-5. PubMed ID: 2864333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of psychopathology on the ability of schizophrenic patients to give informed consent.
    Schachter D; Kleinman I; Prendergast P; Remington G; Schertzer S
    J Nerv Ment Dis; 1994 Jun; 182(6):360-2. PubMed ID: 7911156
    [No Abstract]   [Full Text] [Related]  

  • 7. [Patient knowledge regarding tardive dyskinesia].
    Haberfellner EM; Rittmannsberger H
    Nervenarzt; 2006 Mar; 77(3):333-7. PubMed ID: 16552613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues.
    Brabbins C; Butler J; Bentall R
    Br J Psychiatry; 1996 May; 168(5):540-4. PubMed ID: 8733791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Informing patients about tardive dyskinesia.
    Munetz MR; Roth LH
    Arch Gen Psychiatry; 1985 Sep; 42(9):866-71. PubMed ID: 2864030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consent to treatment.
    Jackson GA; McGrath A
    Br J Psychiatry; 1996 Sep; 169(3):382-3. PubMed ID: 8879733
    [No Abstract]   [Full Text] [Related]  

  • 11. Informing patients about tardive dyskinesia: four-year follow up of a trial of patient education.
    Chaplin R; Timehin C
    Aust N Z J Psychiatry; 2002 Feb; 36(1):99-103. PubMed ID: 11929445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consent to treatment.
    Laugharne J; Arcelsus J; Davies A
    Br J Psychiatry; 1996 Sep; 169(3):382. PubMed ID: 8879732
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention and management of tardive dyskinesia.
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):14-8. PubMed ID: 2858473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Legal aspects of neuroleptic-induced movement disorders.
    Wettstein RM
    Leg Med; 1985; ():117-79. PubMed ID: 2872562
    [No Abstract]   [Full Text] [Related]  

  • 15. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical issues in drug selection for schizophrenia.
    Jeffries JJ
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S70-4. PubMed ID: 7504571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic-induced emesis: a new indication for clozapine?
    Bustillo JR; Buchanan RW
    Biol Psychiatry; 1995 Aug; 38(3):194-5. PubMed ID: 7578665
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of schizophrenia from the viewpoint of the patient. Studies on the course of treatment and neuroleptic treatment from a personal perspective].
    Windgassen K
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1989; 58():1-169. PubMed ID: 2576099
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroleptic withdrawal in schizophrenic patients.
    Baldessarini RJ; Viguera AC
    Arch Gen Psychiatry; 1995 Mar; 52(3):189-92. PubMed ID: 7872842
    [No Abstract]   [Full Text] [Related]  

  • 20. Tardive dyskinesia as a risk factor for negative symptoms.
    Wright P; Taylor M
    Br J Psychiatry; 1994 May; 164(5):700-1; author reply 702. PubMed ID: 7921731
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.